Rheumatology Academy

Where education meets excellence.
The latest rheumatology CME
& clinical updates you need.

Where education meets excellence.
The latest rheumatology CME & clinical updates you need.

Unpacking the Complexity of Psoriatic Arthritis
Unpacking the Complexity of Psoriatic Arthritis
Living Rheum
Unpacking the Complexity of Psoriatic Arthritis
- Lawrence H. Brent
JAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
JAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
Living Rheum
JAK Inhibitors in Psoriatic Arthritis: Reassessing Safety in the Real World
Shared CD8+ T Cell Clones Link Skin and Joint Inflammation in Psoriatic Arthritis
Shared CD8+ T Cell Clones Link Skin and Joint Inflammation in Psoriatic Arthritis
Living Rheum
Shared CD8+ T Cell Clones Link Skin and Joint Inflammation in Psoriatic Arthritis
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
CME/CE
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
1.00 credit
- Flavia Castelino, MD
- Benjamin Korman, MD
1.00 credit
Progress and Practical Limits with AI in Psoriatic Arthritis
Progress and Practical Limits with AI in Psoriatic Arthritis
AudioAbstracts
Progress and Practical Limits with AI in Psoriatic Arthritis
- Ryan Quigley
Navigating the Modern PsA Treatment Landscape
Navigating the Modern PsA Treatment Landscape
Living Rheum
Navigating the Modern PsA Treatment Landscape
Can FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
Can FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
AudioAbstracts
Can FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
- Ryan Quigley
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Living Rheum
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
- Steve Jackson, PharmD
- Marc Scherlinger, MD, PhD